Assign modules on offcanvas module position to make them visible in the sidebar.

Testimonials

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Sandro Rosell
FC Barcelona President
Sunday, September 24, 2017

Health

Israel’s ReWalk is working with Harvard on developing an ‘exosuit’ to help MS and stroke patients regain mobility

ReWalk, the pioneering Israeli company that makes a robotic exoskeleton to get people with spinal-cord injuries on their feet, premiered the prototype for a soft suit intended to assist stroke survivors and patients suffering from multiple sclerosis regain mobility.

There are an estimated 3 million stroke survivors with lower-limb disability in the United States alone.

ReWalk’s flagship product, ReWalk 6.0, includes robotic leg attachments that can weigh up to 50 pounds. The new suit – called “Restore” – uses similar technologies and mechanics, but is much lighter and simpler.

Restore looks like the kind of harness

BrainStorm Cell Therapeutics’ NurOwn platform enhances a patient's own adult stem cells to halt progression of incurable neurodegenerative diseases.

BrainStorm Cell Therapeutics of Petah Tikva is recruiting American patients for a Phase 3 clinical study of its NurOwn stem-cell treatment intended to halt progression of amyotrophic lateral sclerosis (ALS).

The announcement was made in a patient webinar last week.

The NurOwn platform grew out of a technique developed at Tel Aviv University for

Wouldn’t it be great if our most difficult days came with Hollywood-happy endings?

In the movies, when faced with the worst possible situations, our heroes rise to the occasion and find strength they never knew they had. But those who experience real-life traumas are just as likely to end up questioning their faith in God, their family and themselves.

The scars, both physical and emotional, may never completely heal. And it can take years to find “meaning” from it all.

Even those who seem

Israeli researchers discover that using cells from the host patient to repair tissues in the heart can be toxic

For patients with severe and end-stage heart failure there are few treatment options left apart from transplants and stem-cell therapy. But a new Israeli study finds that stem-cell therapy may harm heart-disease patients.

The research, led by Prof. Jonathan Leor of Tel Aviv University’s Sackler Faculty of Medicine and Sheba Medical Center and conducted by TAU’s Dr. Nili

Israeli human-on-a-chip platform has the unique ability to predict risk of toxicity in pharma and cosmetic product candidates without animal testing

After spending an average of $2.5 billion to develop a single new drug, sometimes pharma companies have to pull it from the market due to a bad outcome that was not detected in clinical studies.

That’s what happened in 2000, when a promising Type 2 diabetes drug called troglitazone led to idiosyncratic (unexplained) liver damage in one of every